WO2023152719 - COMPOSITION FOR USE IN THE PREVENTION AND THE TREATMENT OF INFECTIONS WITH SARS-COV-2 VIRUSES
National phase entry:
Publication Number
WO/2023/152719
Publication Date
17.08.2023
International Application No.
PCT/IB2023/051295
International Filing Date
13.02.2023
Title **
[English]
COMPOSITION FOR USE IN THE PREVENTION AND THE TREATMENT OF INFECTIONS WITH SARS-COV-2 VIRUSES
[French]
COMPOSITION DESTINÉE À ÊTRE UTILISÉE DANS LA PRÉVENTION ET LE TRAITEMENT D'INFECTIONS PAR LES VIRUS SARS-COV-2.
Applicants **
BIOCHEMICAL RESEARCH A.E.I.E.
Inventors
Priority Data
102022000002690
14.02.2022
IT
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1958 | |
| EPO | Filing, Examination, Granting | 8376 | |
| Japan | Filing, Examination, Granting | 2000 | |
| South Korea | Filing, Examination, Granting | 1754 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,828
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A composition for use as a drug in a method of treating and preventing SARS-CoV-2 viruses causing COVID-19 in a host, typically a human being, characterised by being composed of a compound of Potassium Bicarbonate and D-Ribose in aqueous solution.[French]
L'invention concerne une composition destinée à être utilisée comme médicament dans une méthode de traitement et de prévention contre les virus SARS-CoV-2 causant la COVID-19 chez un hôte, typiquement un être humain, caractérisée en ce qu'elle est composée d'un composé de bicarbonate de potassium et de D-ribose en solution aqueuse.